Asha Nayak
Health Investments at Johnson & Johnson Innovation
San Francisco Bay Area
Overview
Work Experience
Board Member
2021 - Current
Global Head of Consumer Health Investments
2020
• Leading investment strategy, global portfolio (>22 companies), and investment team • Guiding growth of portfolio companies through Covid-19 pandemic and market disruptions • Two companies achieved sustained profitability. Three were acquired by scale partners. • Delivered 8 successful financial exits, 1 acquisition, and 2 strategic partnerships for J&J • Shaping J&J growth strategy and facilitating partnerships between J&J and venture portfolio. • Member of JJDC’s Investment Committee investing across Consumer Health, MedTech, and Pharmaceuticals. Deploying~$500M/yr with $3.6Bn invested across >170 companies • Board Leadership QUIP - New York, NY – Board Director READY, SET, FOOD - Los Angeles, CA – Board Director CALA HEALTH - Foster City, CA – Board Director HIDOC / CARA CARE - Berlin, Germany – Board Director PIVOT HEALTH, Redwood City, CA – Board Director DERMALA, San Diego, CA – Board Director PICNIC HEALTH, New York, NY - Board Director CHALKBOARD HEALTH, Princeton, NJ – Board Director FOUNDERS FACTORY of NEW YORK, New York, NY – Board Director THIRTY MADISON, New York, NY – Board Observer INFINANT HEALTH, Davis, CA - Board Observer
ER Physician
2001
Strategic Contributor
2018 - 2020
Independent Director
2017 - 2020
• Guided commercialization of Zuranolone, the first-ever drug to treat post-partum depression. • Advised on digital, clinical, and commercialization strategies as company pursued Phase I, II, and III clinical trials and FDA submissions in major depression, anxiety, tinnitus, epilepsy, and other neuropsychiatric conditions for a large pipeline of new chemical entities showing early signs of efficacy. • Member of “Science and Technology” and “Nominating and Corporate Governance” Committees.
SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
Raised $2,701,000,000.00 from Biogen.
Independent Director
2014 - 2020
• Guided product, GTM, clinical / regulatory, and fundraising strategies. Attracted critical corporate investment dollars and partnerships. Grew the team to include a CMO and cross-functional Board. • Helped CEO to build technology, investor, and partner networks in the US as the company moved from Australia to the US.
Chief Medical Officer
2012 - 2018
An ecosystem of software & hardware vendors, integrators and solution providers focused on adoption of NFV and SDN-based solutions.
Vice President
2010 - 2012
• Led evaluations of over 300 life science investment opportunities across medical devices, pharmaceuticals, medical diagnostics, and healthcare IT for a $450M fund. • Sourced and negotiated deals to deal closure, deploying $114M+ across syndicates; $34.5M for NLVP. • Board service iRHYTHM (NASDAQ: IRTC), San Francisco, CA – Board Observer CARDIOKINETIX, Menlo Park, CA – Board Observer SPIRACUR, Sunnyvale, CA – Board Observer ALTURA MEDICAL, San Clemente, CA – Board Observer
New Leaf Venture Partners is a venture capital firm focused on investments in healthcare technology companies.
Senior Principal Scientist & Clinical Advisor
2002 - 2009
Medtronic is a healthcare technology company that designs and develops AI-based products and solutions for the medical industry.
Raised $9,105,978,217.00 from NHS England.
Resident
1998 - 2001